MedTrace Logo

Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease

NCT02739750 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-01-26

No results posted yet for this study

Summary

Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same age. It is not clear if there will be changes in the marrow fact content in those with CKD on Pioglitazone. In people with normal kidney function, thiazolidinedione group of drugs have had variable effects on bone marrow fat content, as measured by MRS. This is important as changes in marrow fat are likely related to changes in the bone in patients with chronic kidney disease.

Conditions

  • Polycystic Kidney Diseases

Interventions

OTHER

No intervention

There is no intervention for this study. It is a MRS.

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Ranjani Moorthi, MD · Faculty

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02739750 on ClinicalTrials.gov